Pinacidil, a new vasodilator: Pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1983-07

AUTHORS

J. E. Carlsen, T. Kardel, H. Æ. Jensen, M. Tangø, J. Trap-Jensen

ABSTRACT

In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I–II). In all patients a decrease in diastolic blood pressure to below 100 mmHg, or a fall exceeding 15 mmHg, was obtained 2 h after tablet intake (p<0.02), but in only two patients was the effect maintained after 10 hours (n.s.). At a mean serum concentration of 100 ng/ml 2 h after pinacidil 30 mg, the mean blood pressure had decreased by 14 and 12.7 mmHg in the supine and erect positions, respectively (p<0.05). In contrast, mean blood pressure 10 h after the same dose was unchanged, when the mean serum concentration was 47.5 ng/ml. No change in heart rate was observed. Pharmacokinetic and pharmacodynamic investigations showed a tendency towards a more gradual and longer lasting antihypertensive effect and serum concentration-time curve after the retarded tablet than the previous tablet. Pinacidil 40 mg in the retarded tablet reduced mean blood pressure and increased heart rate for at least 8 h. There was a linear correlation between the serum concentration and the changes in mean blood pressure, and between the changes in mean blood pressure and in heart rate. There was no indication of tachyphylaxis. A serum level of 50 ng/ml of pinacidil appeared to be the minimal effective concentration. The side effect consisted of fluid retention, and the body weight increased by 1.0 kg (p<0.05); four patients complained of oedema. Therapy was discontinued in one patient after a fainting episode following an increase in the dose. Thus, pinacidil was able to lower blood pressure during monotherapy for 4 weeks provided that an adequate serum concentration was achieved. The present retarded tablet formulation is not suitable for b. d. dosing. The tendency towards fluid-retention suggests that pinacidil should be used in combination with a diuretic. More... »

PAGES

557-561

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00542128

DOI

http://dx.doi.org/10.1007/bf00542128

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048586909

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/6653652


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Delayed-Action Preparations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guanidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kinetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pinacidil", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carlsen", 
        "givenName": "J. E.", 
        "id": "sg:person.01172441075.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172441075.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kardel", 
        "givenName": "T.", 
        "id": "sg:person.015552033506.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015552033506.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jensen", 
        "givenName": "H. \u00c6.", 
        "id": "sg:person.01123721253.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123721253.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.415046.2", 
          "name": [
            "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark", 
            "Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tang\u00f8", 
        "givenName": "M.", 
        "id": "sg:person.01170325401.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170325401.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.415046.2", 
          "name": [
            "Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark", 
            "Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trap-Jensen", 
        "givenName": "J.", 
        "id": "sg:person.0101162757.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0101162757.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01975139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036141189", 
          "https://doi.org/10.1007/bf01975139"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1983-07", 
    "datePublishedReg": "1983-07-01", 
    "description": "In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I\u2013II). In all patients a decrease in diastolic blood pressure to below 100 mmHg, or a fall exceeding 15 mmHg, was obtained 2 h after tablet intake (p<0.02), but in only two patients was the effect maintained after 10 hours (n.s.). At a mean serum concentration of 100 ng/ml 2 h after pinacidil 30 mg, the mean blood pressure had decreased by 14 and 12.7 mmHg in the supine and erect positions, respectively (p<0.05). In contrast, mean blood pressure 10 h after the same dose was unchanged, when the mean serum concentration was 47.5 ng/ml. No change in heart rate was observed. Pharmacokinetic and pharmacodynamic investigations showed a tendency towards a more gradual and longer lasting antihypertensive effect and serum concentration-time curve after the retarded tablet than the previous tablet. Pinacidil 40 mg in the retarded tablet reduced mean blood pressure and increased heart rate for at least 8 h. There was a linear correlation between the serum concentration and the changes in mean blood pressure, and between the changes in mean blood pressure and in heart rate. There was no indication of tachyphylaxis. A serum level of 50 ng/ml of pinacidil appeared to be the minimal effective concentration. The side effect consisted of fluid retention, and the body weight increased by 1.0 kg (p<0.05); four patients complained of oedema. Therapy was discontinued in one patient after a fainting episode following an increase in the dose. Thus, pinacidil was able to lower blood pressure during monotherapy for 4 weeks provided that an adequate serum concentration was achieved. The present retarded tablet formulation is not suitable for b. d. dosing. The tendency towards fluid-retention suggests that pinacidil should be used in combination with a diuretic.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00542128", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "keywords": [
      "mean blood pressure", 
      "blood pressure", 
      "mean serum concentration", 
      "serum concentrations", 
      "heart rate", 
      "essential hypertension", 
      "serum concentration-time curve", 
      "indication of tachyphylaxis", 
      "untreated essential hypertension", 
      "adequate serum concentrations", 
      "diastolic blood pressure", 
      "concentration-time curve", 
      "minimal effective concentration", 
      "open study", 
      "tablet intake", 
      "antihypertensive effect", 
      "fainting episodes", 
      "serum levels", 
      "new vasodilator", 
      "fluid retention", 
      "pharmacodynamic investigations", 
      "same dose", 
      "side effects", 
      "pinacidil", 
      "patients", 
      "body weight", 
      "erect position", 
      "tablet formulation", 
      "hypertension", 
      "mmHg", 
      "effective concentration", 
      "dose", 
      "weeks", 
      "release tablets", 
      "tachyphylaxis", 
      "monotherapy", 
      "tablets", 
      "diuretics", 
      "vasodilators", 
      "edema", 
      "supine", 
      "pharmacodynamics", 
      "therapy", 
      "pharmacokinetics", 
      "doses", 
      "intake", 
      "rate", 
      "episodes", 
      "pressure", 
      "effect", 
      "concentration", 
      "indications", 
      "changes", 
      "hours", 
      "linear correlation", 
      "fall", 
      "levels", 
      "decrease", 
      "weight", 
      "study", 
      "contrast", 
      "correlation", 
      "increase", 
      "tendency", 
      "retention", 
      "combination", 
      "investigation", 
      "curves", 
      "formulation", 
      "position"
    ], 
    "name": "Pinacidil, a new vasodilator: Pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension", 
    "pagination": "557-561", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048586909"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00542128"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "6653652"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00542128", 
      "https://app.dimensions.ai/details/publication/pub.1048586909"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_174.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00542128"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00542128'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00542128'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00542128'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00542128'


 

This table displays all metadata directly associated to this object as RDF triples.

223 TRIPLES      21 PREDICATES      111 URIs      102 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00542128 schema:about N03f0bc944d77481391daba740026948c
2 N2961ec759e03492196e7ddfe755d72f2
3 N2e76afc6d34a4f2a949e3c762b5da4e2
4 N3462402388c84cc5bd86addb170bc3e0
5 N3c4b78fc0e2d4cbaaf32706f1ba87818
6 N4801430b29df4b60b0bd24d0dec0f882
7 N61c767cf54f3480ea7e71230a1ce5bb2
8 N9044bea3a62649b286d630e4fd082da2
9 Na1c3117a25e848d2ae73d526e8f4e45a
10 Nae460c9327a0441bafbd90d185d8ee52
11 Nb2c590c0f00e4fc6becbc0b204ebe4fd
12 Nc6e1de7248f24d3c8d7cfd764e831560
13 Nce1ad0cd7aba44caa3e9468376196cf7
14 Ne5eee7bfbde7437da447d4bb15caeecb
15 anzsrc-for:11
16 anzsrc-for:1102
17 schema:author Naf54c2b8fd0f4e4483b1349a99b87301
18 schema:citation sg:pub.10.1007/bf01975139
19 schema:datePublished 1983-07
20 schema:datePublishedReg 1983-07-01
21 schema:description In an open study increasing doses of a retarded tablet formulation of pinacidil were given twice daily for four weeks to 9 patients with untreated essential hypertension (WHO I–II). In all patients a decrease in diastolic blood pressure to below 100 mmHg, or a fall exceeding 15 mmHg, was obtained 2 h after tablet intake (p<0.02), but in only two patients was the effect maintained after 10 hours (n.s.). At a mean serum concentration of 100 ng/ml 2 h after pinacidil 30 mg, the mean blood pressure had decreased by 14 and 12.7 mmHg in the supine and erect positions, respectively (p<0.05). In contrast, mean blood pressure 10 h after the same dose was unchanged, when the mean serum concentration was 47.5 ng/ml. No change in heart rate was observed. Pharmacokinetic and pharmacodynamic investigations showed a tendency towards a more gradual and longer lasting antihypertensive effect and serum concentration-time curve after the retarded tablet than the previous tablet. Pinacidil 40 mg in the retarded tablet reduced mean blood pressure and increased heart rate for at least 8 h. There was a linear correlation between the serum concentration and the changes in mean blood pressure, and between the changes in mean blood pressure and in heart rate. There was no indication of tachyphylaxis. A serum level of 50 ng/ml of pinacidil appeared to be the minimal effective concentration. The side effect consisted of fluid retention, and the body weight increased by 1.0 kg (p<0.05); four patients complained of oedema. Therapy was discontinued in one patient after a fainting episode following an increase in the dose. Thus, pinacidil was able to lower blood pressure during monotherapy for 4 weeks provided that an adequate serum concentration was achieved. The present retarded tablet formulation is not suitable for b. d. dosing. The tendency towards fluid-retention suggests that pinacidil should be used in combination with a diuretic.
22 schema:genre article
23 schema:isAccessibleForFree false
24 schema:isPartOf N6481bff3508b4f839ad283fc77335b5e
25 Nc3ce4e503509495a945ac094110bf31a
26 sg:journal.1054337
27 schema:keywords adequate serum concentrations
28 antihypertensive effect
29 blood pressure
30 body weight
31 changes
32 combination
33 concentration
34 concentration-time curve
35 contrast
36 correlation
37 curves
38 decrease
39 diastolic blood pressure
40 diuretics
41 dose
42 doses
43 edema
44 effect
45 effective concentration
46 episodes
47 erect position
48 essential hypertension
49 fainting episodes
50 fall
51 fluid retention
52 formulation
53 heart rate
54 hours
55 hypertension
56 increase
57 indication of tachyphylaxis
58 indications
59 intake
60 investigation
61 levels
62 linear correlation
63 mean blood pressure
64 mean serum concentration
65 minimal effective concentration
66 mmHg
67 monotherapy
68 new vasodilator
69 open study
70 patients
71 pharmacodynamic investigations
72 pharmacodynamics
73 pharmacokinetics
74 pinacidil
75 position
76 pressure
77 rate
78 release tablets
79 retention
80 same dose
81 serum concentration-time curve
82 serum concentrations
83 serum levels
84 side effects
85 study
86 supine
87 tablet formulation
88 tablet intake
89 tablets
90 tachyphylaxis
91 tendency
92 therapy
93 untreated essential hypertension
94 vasodilators
95 weeks
96 weight
97 schema:name Pinacidil, a new vasodilator: Pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension
98 schema:pagination 557-561
99 schema:productId N2b34609a32aa40eea24965dc0429d98a
100 N3c2f7483a93c48c18a62a0363b4003ec
101 N9be1283c302c4e0d94d786be2be4cbb1
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048586909
103 https://doi.org/10.1007/bf00542128
104 schema:sdDatePublished 2022-12-01T06:18
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher Nbb349cf7ef4b4901814dddddc2f0fb60
107 schema:url https://doi.org/10.1007/bf00542128
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N03f0bc944d77481391daba740026948c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Adult
113 rdf:type schema:DefinedTerm
114 N2961ec759e03492196e7ddfe755d72f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged
116 rdf:type schema:DefinedTerm
117 N2b34609a32aa40eea24965dc0429d98a schema:name doi
118 schema:value 10.1007/bf00542128
119 rdf:type schema:PropertyValue
120 N2e76afc6d34a4f2a949e3c762b5da4e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Heart Rate
122 rdf:type schema:DefinedTerm
123 N2edcfbd76730482db0762b24c7a056ce rdf:first sg:person.01170325401.35
124 rdf:rest N44eb2c2ed80543b795209ee670a52935
125 N3462402388c84cc5bd86addb170bc3e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Pinacidil
127 rdf:type schema:DefinedTerm
128 N3c2f7483a93c48c18a62a0363b4003ec schema:name pubmed_id
129 schema:value 6653652
130 rdf:type schema:PropertyValue
131 N3c4b78fc0e2d4cbaaf32706f1ba87818 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Guanidines
133 rdf:type schema:DefinedTerm
134 N44eb2c2ed80543b795209ee670a52935 rdf:first sg:person.0101162757.39
135 rdf:rest rdf:nil
136 N4801430b29df4b60b0bd24d0dec0f882 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Female
138 rdf:type schema:DefinedTerm
139 N61c767cf54f3480ea7e71230a1ce5bb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 N6481bff3508b4f839ad283fc77335b5e schema:volumeNumber 25
143 rdf:type schema:PublicationVolume
144 N9044bea3a62649b286d630e4fd082da2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N9be1283c302c4e0d94d786be2be4cbb1 schema:name dimensions_id
148 schema:value pub.1048586909
149 rdf:type schema:PropertyValue
150 Na1c3117a25e848d2ae73d526e8f4e45a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Kinetics
152 rdf:type schema:DefinedTerm
153 Na2a585081b6b4589a0aa2175df585d6c rdf:first sg:person.015552033506.55
154 rdf:rest Nbd898838e6184df69938725ba3f599f6
155 Nae460c9327a0441bafbd90d185d8ee52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Humans
157 rdf:type schema:DefinedTerm
158 Naf54c2b8fd0f4e4483b1349a99b87301 rdf:first sg:person.01172441075.89
159 rdf:rest Na2a585081b6b4589a0aa2175df585d6c
160 Nb2c590c0f00e4fc6becbc0b204ebe4fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Drug Evaluation
162 rdf:type schema:DefinedTerm
163 Nbb349cf7ef4b4901814dddddc2f0fb60 schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 Nbd898838e6184df69938725ba3f599f6 rdf:first sg:person.01123721253.36
166 rdf:rest N2edcfbd76730482db0762b24c7a056ce
167 Nc3ce4e503509495a945ac094110bf31a schema:issueNumber 4
168 rdf:type schema:PublicationIssue
169 Nc6e1de7248f24d3c8d7cfd764e831560 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Delayed-Action Preparations
171 rdf:type schema:DefinedTerm
172 Nce1ad0cd7aba44caa3e9468376196cf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Hypertension
174 rdf:type schema:DefinedTerm
175 Ne5eee7bfbde7437da447d4bb15caeecb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Blood Pressure
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
182 schema:name Cardiorespiratory Medicine and Haematology
183 rdf:type schema:DefinedTerm
184 sg:journal.1054337 schema:issn 0031-6970
185 1432-1041
186 schema:name European Journal of Clinical Pharmacology
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.0101162757.39 schema:affiliation grid-institutes:grid.415046.2
190 schema:familyName Trap-Jensen
191 schema:givenName J.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0101162757.39
193 rdf:type schema:Person
194 sg:person.01123721253.36 schema:affiliation grid-institutes:None
195 schema:familyName Jensen
196 schema:givenName H. Æ.
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123721253.36
198 rdf:type schema:Person
199 sg:person.01170325401.35 schema:affiliation grid-institutes:grid.415046.2
200 schema:familyName Tangø
201 schema:givenName M.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170325401.35
203 rdf:type schema:Person
204 sg:person.01172441075.89 schema:affiliation grid-institutes:None
205 schema:familyName Carlsen
206 schema:givenName J. E.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172441075.89
208 rdf:type schema:Person
209 sg:person.015552033506.55 schema:affiliation grid-institutes:None
210 schema:familyName Kardel
211 schema:givenName T.
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015552033506.55
213 rdf:type schema:Person
214 sg:pub.10.1007/bf01975139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036141189
215 https://doi.org/10.1007/bf01975139
216 rdf:type schema:CreativeWork
217 grid-institutes:None schema:alternateName Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark
218 schema:name Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark
219 rdf:type schema:Organization
220 grid-institutes:grid.415046.2 schema:alternateName Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark
221 schema:name Department of Clinical Physiology, Frederiksberg Hospital, Copenhagen, Denmark
222 Department of Internal Medicine C, Diakonissestiftelsen, Copenhagen, Denmark
223 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...